Abingworth LLP - Mar 21, 2022 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Role: 10%+ Owner
Signature: /s/ John Heard
Stock symbol: JSPR
Transactions as of: Mar 21, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/23/2022, 05:30 PM
Previous filing: Feb 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JSPR	Stock Option (right to buy)	Award	$0	+78K		$0.00	78K	Mar 21, 2022	Voting Common Stock	78K	$3.54	See footnotes	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII.
F2	The option (the "Option") was granted to Kurt von Emster, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. The Option will vest in equal annual installments over three years, commencing on December 7, 2022, subject to the Mr. von Emster's continued service with the Issuer through each vesting date. Under an agreement between Mr. von Emster and the Reporting Person, Mr. von Emster is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of the Reporting Person.
F3	ABV VII may be deemed the indirect beneficial owner of the Option, and Mr. von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Mr. von Emster, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.